
    
      PRIMARY OBJECTIVE:

      I. To provide clinical access to and assess the safety of the investigational agent Gallium
      Ga 68-labeled prostate specific membrane antigen (PSMA)-11 (68Ga-PSMA-11) positron emission
      tomography (PET) at City of Hope National Medical Center for patients co-enrolled on
      Institutional Review Board (IRB) 18517 treatment trial.

      OUTLINE:

      Patients receive gallium Ga 68-labeled PSMA-11 intravenously (IV) over less than 1 minute,
      and then undergo PET over 60 minutes.

      After completion of study, patients are followed up at 1-3 days, and then at 3 weeks.
    
  